PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33728578-0 2021 Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis. Vancomycin 90-100 cystatin C Homo sapiens 0-10 17336280-0 2007 Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Vancomycin 39-49 cystatin C Homo sapiens 6-16 17336280-1 2007 OBJECTIVES: The purpose of this study is to assess the usefulness of the concentration of cystatin C (Cys-C) in serum for predicting the clearance of vancomycin (CLvcm) compared with the serum concentration of creatinine (SCr) in the elderly. Vancomycin 150-160 cystatin C Homo sapiens 90-100 17336280-1 2007 OBJECTIVES: The purpose of this study is to assess the usefulness of the concentration of cystatin C (Cys-C) in serum for predicting the clearance of vancomycin (CLvcm) compared with the serum concentration of creatinine (SCr) in the elderly. Vancomycin 150-160 cystatin C Homo sapiens 102-107 17417082-6 2007 These results suggest that serum cystatin C is a good marker of renal function in comparison with serum creatinine for dose setting of vancomycin, especially in an elderly population. Vancomycin 135-145 cystatin C Homo sapiens 33-43 16778715-0 2006 Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Vancomycin 142-152 cystatin C Homo sapiens 6-16 10472217-0 1999 High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. Vancomycin 36-46 cystatin C Homo sapiens 119-129 10472217-8 1999 We conclude that simultaneous administration of high-dose aprotinin and prophylactic use of gentamicin with vancomycin increased serum concentrations of cystatin C and creatinine in the first postoperative week in patients undergoing cardiac surgery. Vancomycin 108-118 cystatin C Homo sapiens 153-163 33967770-0 2021 Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates. Vancomycin 82-92 cystatin C Homo sapiens 27-37 33496976-0 2021 Correlation between vancomycin clearance and cystatin C-based glomerular filtration rate in paediatric patients. Vancomycin 20-30 cystatin C Homo sapiens 45-55 33496976-1 2021 AIMS: Because of limitations with the serum creatinine-based glomerular filtration rate (GFRcr), estimates of the serum cystatin C-based glomerular filtration rate (GFRcys) are getting attention to predict vancomycin clearance (CLvan). Vancomycin 206-216 cystatin C Homo sapiens 120-130 33496976-10 2021 CONCLUSIONS: Serum cystatin C-based GFR strongly correlates with vancomycin clearance, suggesting the possibility of better prediction models than creatinine-based GFR. Vancomycin 65-75 cystatin C Homo sapiens 19-29 32947559-0 2020 Effect of Cystatin C on Vancomycin Clearance Estimation in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach. Vancomycin 24-34 cystatin C Homo sapiens 10-20 33106257-0 2020 Prediction of Vancomycin Levels using Cystatin C in Overweight and Obese Patients: A Retrospective Cohort Study of Hospitalized Patients. Vancomycin 14-24 cystatin C Homo sapiens 38-48 33106257-1 2020 The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in non-obese patients. Vancomycin 87-97 cystatin C Homo sapiens 41-51 33106257-1 2020 The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in non-obese patients. Vancomycin 87-97 cystatin C Homo sapiens 53-57 33106257-9 2020 This study is the first to examine the role of cysC in predicting vancomycin levels in an exclusively overweight or obese population. Vancomycin 66-76 cystatin C Homo sapiens 47-51 33642514-0 2021 [Assessment of Renal Function and Simulation Using Serum Cystatin-C in an Elderly Patient with Uncontrollable Plasma Vancomycin Levels Due to Muscular Dystrophy: A Case Report]. Vancomycin 117-127 cystatin C Homo sapiens 57-67 32947559-14 2020 CONCLUSIONS: CysC-based equations help better estimate vancomycin CL than bedside Schwartz in critically ill children. Vancomycin 55-65 cystatin C Homo sapiens 13-17 32868529-4 2020 Numerous studies have evaluated medication dosing based on either GFR estimate; vancomycin was the most frequently studied drug and its target level and elimination were better predicted by cystatin C. Vancomycin 80-90 cystatin C Homo sapiens 190-200 32959542-0 2020 A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance. Vancomycin 103-113 cystatin C Homo sapiens 38-48 32959542-7 2020 This indicates the presence of unbiased results in vancomycin clearance prediction by the cystatin C-based eGFR equations. Vancomycin 51-61 cystatin C Homo sapiens 90-100 32959542-9 2020 CONCLUSION: Cystatin C-based eGFR equations are better than creatinine-based eGFR equations in predicting the clearance of vancomycin. Vancomycin 123-133 cystatin C Homo sapiens 12-22 32959542-10 2020 This suggests that utilising cystatin C-based eGFR equations could result in better accuracy and precision to predict vancomycin pharmacokinetic parameters. Vancomycin 118-128 cystatin C Homo sapiens 29-39 32843769-0 2020 Successful Vancomycin Dose Adjustment in a Sepsis patient with Bacterial Meningitis Using Cystatin C. Vancomycin 11-21 cystatin C Homo sapiens 90-100 32843769-1 2020 Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients. Vancomycin 18-28 cystatin C Homo sapiens 0-10 32843769-1 2020 Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients. Vancomycin 30-33 cystatin C Homo sapiens 0-10 25222855-13 2014 CONCLUSIONS: In the SCI population, the use of Chronic Kidney Disease Epidemiology Collaboration cystatin C equation may improve initial vancomycin dosing. Vancomycin 137-147 cystatin C Homo sapiens 97-107 31463971-9 2020 In the Cys C model, age, body weight and cGFR were significant covariates on the clearance rate (CL) of vancomycin (typical value, 6.4 L/hour). Vancomycin 104-114 cystatin C Homo sapiens 7-12 28131530-0 2017 Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. Vancomycin 18-28 cystatin C Homo sapiens 0-10 28131530-1 2017 BACKGROUND: The aim of the study was to determine whether a vancomycin dosing algorithm based on estimated glomerular filtration rate from creatinine and cystatin C levels (eGFRcr-cys) improves target trough concentration achievement compared to an algorithm based on estimated creatinine clearance (eCLcr) in critically ill patients. Vancomycin 60-70 cystatin C Homo sapiens 154-164 32304024-0 2020 A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C. Vancomycin 40-50 cystatin C Homo sapiens 86-96 32304024-1 2020 BACKGROUND AND OBJECTIVES: Renal function has an important influence on the pharmacokinetics of vancomycin, and serum cystatin C (CysC) exhibits accurate predictive performance as a marker for renal function. Vancomycin 96-106 cystatin C Homo sapiens 118-128 32304024-1 2020 BACKGROUND AND OBJECTIVES: Renal function has an important influence on the pharmacokinetics of vancomycin, and serum cystatin C (CysC) exhibits accurate predictive performance as a marker for renal function. Vancomycin 96-106 cystatin C Homo sapiens 130-134 32304024-2 2020 This study aimed to develop a population pharmacokinetics (PopPK) model of vancomycin based on serum CysC in pediatric patients. Vancomycin 75-85 cystatin C Homo sapiens 101-105 32304024-7 2020 Serum CysC and age were significant covariates affecting the pharmacokinetics of vancomycin. Vancomycin 81-91 cystatin C Homo sapiens 6-10 32304024-10 2020 CONCLUSIONS: The pharmacokinetic parameters for vancomycin in pediatric patients were estimated using a serum CysC model. Vancomycin 48-58 cystatin C Homo sapiens 110-114 31541402-0 2020 Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population. Vancomycin 84-94 cystatin C Homo sapiens 49-59 31541402-2 2020 Therefore, we established a cystatin C-based model of vancomycin. Vancomycin 54-64 cystatin C Homo sapiens 28-38 31541402-3 2020 OBJECTIVES: The purpose of this study was to externally verify the PopPK model of vancomycin based on the glomerular filtration rate (GFR) estimated by serum cystatin C in our previous study and to compare the prediction performance of cystatin C (Cys C) and serum creatinine (SCR)-based models. Vancomycin 82-92 cystatin C Homo sapiens 158-168 31541402-3 2020 OBJECTIVES: The purpose of this study was to externally verify the PopPK model of vancomycin based on the glomerular filtration rate (GFR) estimated by serum cystatin C in our previous study and to compare the prediction performance of cystatin C (Cys C) and serum creatinine (SCR)-based models. Vancomycin 82-92 cystatin C Homo sapiens 236-246 31541402-14 2020 CONCLUSION: After comparison, we suggest that cystatin C is a superior renal function marker to serum creatinine for vancomycin PopPK models. Vancomycin 117-127 cystatin C Homo sapiens 46-56 30873627-0 2019 A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function. Vancomycin 38-48 cystatin C Homo sapiens 91-101 30873627-1 2019 OBJECTIVES: This study aimed to establish a vancomycin population pharmacokinetics (PPK) model based on serum cystatin C and to optimize dosing for achieving targeted steady-state trough concentrations (Css ) of 10-15 and 15-20 mg/l. Vancomycin 44-54 cystatin C Homo sapiens 110-120 30873627-3 2019 A vancomycin PPK model was built with glomerular filtration rate (GFR) as a renal covariate estimated by cystatin C. Vancomycin 2-12 cystatin C Homo sapiens 105-115 30873627-11 2019 CONCLUSIONS: A vancomycin PPK model with cystatin C as the renal marker has good stability and predictability. Vancomycin 15-25 cystatin C Homo sapiens 41-51 26692877-0 2015 Usefulness of serum cystatin C to determine the dose of vancomycin in neonate. Vancomycin 56-66 cystatin C Homo sapiens 20-30 26692877-2 2015 In the present study, we aimed to assess the usefulness of serum cystatin C (Cys-C) concentration, compared with serum creatinine (SCr) concentration, for predicting vancomycin clearance (CLvcm) in neonates. Vancomycin 166-176 cystatin C Homo sapiens 65-75 25222855-7 2014 METHODS: Patients with SCI receiving vancomycin with measured serum creatinine, cystatin C, and steady-state serum vancomycin concentration were identified. Vancomycin 37-47 cystatin C Homo sapiens 80-90 23195915-12 2013 CysC can estimate the daily dose of Van, and may improve therapeutic success rates of MRSA-infected patients. Vancomycin 36-39 cystatin C Homo sapiens 0-4 24887089-0 2014 Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Vancomycin 26-36 cystatin C Homo sapiens 6-16 24887089-8 2014 Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care. Vancomycin 45-55 cystatin C Homo sapiens 0-10 23195915-0 2013 Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations. Vancomycin 41-51 cystatin C Homo sapiens 90-100 23195915-1 2013 OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Vancomycin 100-110 cystatin C Homo sapiens 28-38 23195915-1 2013 OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Vancomycin 100-110 cystatin C Homo sapiens 40-44 23195915-1 2013 OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Vancomycin 112-115 cystatin C Homo sapiens 28-38 23195915-1 2013 OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Vancomycin 112-115 cystatin C Homo sapiens 40-44 19933799-10 2010 Use of the serum cystatin C concentration as a marker of renal function for prediction of serum VAN concentrations may be useful. Vancomycin 96-99 cystatin C Homo sapiens 17-27 20863668-0 2010 Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Vancomycin 13-23 cystatin C Homo sapiens 155-165 20636878-0 2010 Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. Vancomycin 56-66 cystatin C Homo sapiens 20-30 23341711-0 2013 Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. Vancomycin 41-51 cystatin C Homo sapiens 6-16 23341711-1 2013 We developed a population pharmacokinetic model of vancomycin by integrating the effects of cystatin C and other demographic factors in a large population of Korean patients with normal serum creatinine concentrations to elucidate the precise role of serum cystatin C concentrations in the prediction of vancomycin clearance. Vancomycin 51-61 cystatin C Homo sapiens 92-102 23341711-1 2013 We developed a population pharmacokinetic model of vancomycin by integrating the effects of cystatin C and other demographic factors in a large population of Korean patients with normal serum creatinine concentrations to elucidate the precise role of serum cystatin C concentrations in the prediction of vancomycin clearance. Vancomycin 51-61 cystatin C Homo sapiens 257-267 23341711-7 2013 The use of serum cystatin C as marker of vancomycin clearance for more accurate predictions of serum vancomycin concentrations could be useful, particularly among patients with normal serum creatinine concentrations. Vancomycin 41-51 cystatin C Homo sapiens 17-27 23341711-7 2013 The use of serum cystatin C as marker of vancomycin clearance for more accurate predictions of serum vancomycin concentrations could be useful, particularly among patients with normal serum creatinine concentrations. Vancomycin 101-111 cystatin C Homo sapiens 17-27 18077923-0 2007 Hoek"s formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Vancomycin 168-178 cystatin C Homo sapiens 18-28 18077923-3 2007 In this study, we compared the predictive performance of the serum vancomycin trough concentration predicted using serum cystatin C-based formulas. Vancomycin 67-77 cystatin C Homo sapiens 121-131